Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MASP2 | O00187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730693 | 1.00 | HTT (0.47) | HTTKDM4ESMN1; SMN2HCAR2HDAC3 | |
| SCHEMBL3045538 | 0.85 | HTT (0.47) | HTTKDM4ESMN1; SMN2HCAR2HDAC3 | |
| SCHEMBL226234 | 0.85 | HTT (0.47) | HTTKDM4ESMN1; SMN2HCAR2HDAC3 | |
| SCHEMBL12148887 | 0.83 | GLA (0.44) | HTTKDM4EALDH1A1ALOX15LMNA | |
| SCHEMBL11541783 | 0.82 | LTA4H (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11541789 | 0.82 | LTA4H (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12148886 | 0.82 | ALOX15 (0.36) | HTTKDM4ESMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL12148884 | 0.80 | RNF4 (0.37) | HTTKDM4ESMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL29049622 | 0.80 | LTA4H (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8348919 | 0.79 | MTNR1A (0.36) | HTTKDM4ESMN1; SMN2HCAR2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138225-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138225-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138225-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-7842727-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842727-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842727-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100143961-A1 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20050282890-A1 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | LAN-HARGEST HSUAN-YIN | 2005-12-22 | — | — | US | disclosed |
| EP-1511715-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON TRIHALOMETHYLCARBONYL COMPOUNDS | Errant Gene Therapeutics, LLC (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1511477-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETOEPOXIDE COMPOUNDS | Errant Gene Therapeutics, LLC (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1511729-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHACHALCOGENMETHYLCARBONYL COMPOUNDS | Errant Gene Therapeutics, LLC (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040029903-A1 | Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds | BEACON LABORATORIES, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20040029922-A1 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | BEACON LABORATORIES, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20040023944-A1 | Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds | BEACON LABORATORIES, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099789-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHACHALCOGENMETHYLCARBONYL COMPOUNDS | ERRANT GENE THERAPEUTICS, LLC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099272-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETOEPOXIDE COMPOUNDS | ERRANT GENE THERAPEUTICS, LLC (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099760-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON TRIHALOMETHYLCARBONYL COMPOUNDS | ERRANT GENE THERAPEUTICS, LLC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029922-A1 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | HDAC1, KAT2A, HDAC10 | HTT 80/4885KDM4E 412/4885SMN1; SMN2 132/4885 |
| US-20040023944-A1 | Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds | HDAC1, HDAC10, KAT2A | HTT 72/4885KDM4E 631/4885SMN1; SMN2 119/4885 |
| US-20040029903-A1 | Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds | HDAC1, HDAC3, HDAC9 | HTT 48/4885KDM4E 1034/4885SMN1; SMN2 89/4885 |
| US-20050282890-A1 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | HDAC1, KAT2A, HDAC10 | HTT 80/4885KDM4E 412/4885SMN1; SMN2 132/4885 |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC6, HDAC5 | HTT 86/4885KDM4E 1872/4885SMN1; SMN2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.